LGALS3 and type 2 diabetes mellitus: In epidemiological studies, patients with prediabetes or type 2 diabetes exhibited elevated systemic galectin-3, which correlates inversely with glycosylated hemoglobin [8] and positively with insulin sensitivity [9], supporting that galectin-3 is more likely to be an alternative biomarker in the progression of diabetes.